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ABSTRACT 
 
Gene therapy is a technique used to inactivate, replace or insert a corrective copy of a 
defective gene in order to help diseased tissues to function properly. Gene therapy is a promising 
treatment for many diseases cancer, cystic fibrosis, and Parkinson’s. There are different methods 
to introduce a gene to the cell; one of them is the use of viruses. Among viruses, lentiviruses have 
been popular vectors for gene delivery due to their efficient mode of gene delivery. However, the 
non-specific delivery of genes associated with viruses may result in undesirable side effects. 
Here, we propose a heterogeneous nanoparticle delivery system for targeted delivery of lentiviral 
particles containing a therapeutic gene. The heterogeneous nanoparticles (NPs) consist of the 
low density lipoprotein receptor 3 (LDLR3) and the keratinocyte growth factor (KGF), each fused 
to elastin-like-polypeptides (ELPs), LDLR3-ELP and KGF-ELP, respectively. Our results show 
that while homogeneous nanoparticles comprising of LDLR3-ELP alone blocked viral 
transduction, heterogeneous nanoparticles comprising of KGF-ELP and LDLR3-ELP enhanced 
viral transduction in cells expressing high levels of the KGF receptors (KGFR) compared to cells 
expressing low levels of KGF receptors. Overall, this novel design may help with the targeting of 
specific cells that overexpressed growth factor such as KGFR. 
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CHAPTER 1: OVERVIEW OF GENE THERAPY 
 
Gene therapy has been evolving for decades. It is a technique used to deliver DNA into a cell 
to inactivate mutated gene, replace a mutated gene, or insert a corrective copy of a defective 
gene in order to help diseased tissues and/or organs to function properly. However, there are 
many challenges that are encountered in this field. For gene disorders, introducing the missing 
gene is difficult because many cells have to be able to uptake the gene where the gene has to be 
activated and gets encoded. When introducing a gene to specific cells, the success of delivering 
the gene to the targeted cells is crucial. The fact that cells can shut genes down due to exhibiting 
irregular behaviors causes most disorders to be incurable. Most importantly, creating gene 
delivery vectors has been challenging because these vectors have to be able to surpass the 
body’s natural immune system to reach the targeted site and also incorporate the gene that can 
get activated and stay stable. 
Gene therapy has been used for diseases such as cancer [1], cystic fibrosis [2], ischemia [3], 
Alzheimer [4], Parkinson [5] and primary immune-deficiencies [6]. For gene therapy to be 
successful, the therapeutic gene must reach the targeted cells, then be expressed and sustained 
in the cells. There are different methods of delivering genes to cells. The most common methods 
are the use of non-viral vectors and viral vectors. 
1.1 Gene Delivery Techniques 
1.1.1 Non-Viral Delivery Methods 
Non-viral delivery methods deliver the gene of interest into cells by using natural or synthetic 
compounds or physical forces [7]. This includes lipid mediated gene delivery [8], cationic polymers 
[9], electroporation [10] and microinjection [11]. Lipid mediated gene delivery is using liposomes 
DNA complexes to deliver the DNA to the nucleus. Cationic polymers is using positive charged 
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polymers that bind to the negatively charge DNA and delivers the DNA through endocytosis. 
Electroporation is using electric pulses to open the pores in the cell membranes to introduce the 
DNA to the cells. Microinjection is using microneedles to inject a liquid substance containing the 
DNA to cells. Table 1 below summarizes the advantages and disadvantages of the non-viral 
vectors. 
Table 1 Advantages and disadvantages of the non-viral vectors 
Methods Advantages Disadvantages 
Lipid Mediated 
gene delivery 
Low immunogenicity [12-14] 
High level of transgene expression 
after direct administration [15] 
Low Cost [13] 
Easy to use in most cell types [12] 
Simple and fast procedure with high 
reproducibility [12, 16] 
Low efficiency in primary and 
non-dividing cells [12, 15] 
 
Low in vivo efficiency [12] 
Cationic 
Polymers 
Poly-ethylenimine (PEI)-high 
transfection activity in vitro [17, 18] 
Poly-l-lysine (PLL)-biodegradable [18] 
Large size of DNA can be transfected 
[16] 
Easy to produce and have large scale 
[15] 
PEI-non-biodegradable [17] 
 
PLL-low transfection efficiency 
[18] 
 
Cytotoxic [16-18] 
 
Electroporation 
High levels of transgene expression in 
several organs [15] 
Can cause local tissue damage 
and inflammation [15] 
Parameter optimization for 
different cell types [15] 
Depends on high plasmid DNA 
concentration [15] 
Microinjection 
Small amount of DNA required of 
transference [15] 
Extremely difficult, low 
performance [15] 
 
The advantages of non-viral delivery methods compared to viral delivery methods are that the 
non-viral methods have less immunotoxicity than viral delivery methods and that viral delivery 
methods have the potential to cause insertional mutagenesis [7, 19]. However, the drawbacks of 
using non-viral delivery methods are that they have lower transfection efficiency compared to viral 
delivery methods [19] and that viruses especially lentiviruses can integrate into both dividing and 
non-dividing cells’ genomes. 
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1.1.2 Viral Delivery Methods 
Viral delivery methods are using viral vectors to deliver the DNA into the host cells. Viruses 
such as herpes simplex viruses [20], adenoviruses [21], adeno-associated viruses [22], and 
lentiviruses [23] are utilized as vectors for gene delivery. Table 2 below summarizes the 
advantages and disadvantages of the viral vectors. Due to their efficient mode of gene delivery, 
viruses such as lentiviruses are popular vectors for gene delivery [24].  Lentiviral vectors are 
essential because they can infect both dividing and non-dividing cells [25-27], they integrate into 
the target cell’s genome [17, 28, 29], and they have long term stable expression of a transgene 
[17, 29]. The process of introducing viral particles to cells is called transduction. In clinical trials, 
the transduction efficiency is critical because higher desired cells that are infected by the virus 
have a higher chance of expressing the desired gene. However, when the viral particles are not 
delivered to the desired cells, side effects can occur. In clinical trials, safety is priority. Scientists 
check for toxicity, immunogenicity, and insertional mutagenesis. Toxicity is the quality of the 
treatment being toxic to cells that can lead to cell death. Treatments that are targeting cancer 
cells are beneficial, however if they target healthy cells, that raise concerns. Immunogenicity is 
an induction of the immune response. When this induction occurs, that can result a loss in efficacy 
and production of antibodies. Insertional mutagenesis occurs when the insert changes the DNA, 
hence mutation in the DNA. The mutation in the DNA can cause other diseases. 
Table 2 Advantages and disadvantages of viral vectors 
Methods Advantages Disadvantages 
Adenovirus 
Can transduce in both dividing and 
non-dividing cells [15, 17, 29] 
 
Well suited as oncolytic vector [17, 
21] 
 
Able to deliver large DNA particles 
[17, 30] 
Does not integrate into cell’s 
genome [29] 
 
Immunogenic [6, 15, 29, 30] 
 
High levels of pre-existing immunity 
[29] 
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Table 2 (Continued) 
Adeno 
Associated 
Virus 
Integrate into specific site on 
chromosome 19 [6, 17] 
Limited transgene capacity [6, 15, 
17, 29] 
 
Need co-infection by helper virus 
[29] 
Herpes 
Simplex 
Virus 
Able to deliver large DNA particles 
[17, 29, 30] 
 
Well suited as neurotropic vector [17] 
Difficult to keep virus action under 
control [30] 
 
High levels of pre-existing immunity 
[29] 
Lentivirus 
Can integrate into host cell genome 
[17, 29] 
 
Wide cellular tropism [29] 
 
Ability to infect both dividing and non-
dividing cells [17, 25-27, 30] 
 
Long term stable expression of a 
transgene [17] 
High risk of insertional mutagenesis 
[29] 
 
Concerns of biosafety [30] 
 
1.1.3 Lentiviruses 
Lentiviruses are diploid viruses (two strands of RNA) from the retroviridae family [31]. 
Lentiviral plasmids are modified to prevent the formation of replication competent lentiviruses. 
The three plasmids that are used to create lentiviruses are an envelope plasmid, a packaging 
plasmid, and a transfer plasmid. The envelope is a vesicular stomatitis virus glycoprotein 
envelope plasmid which is used to target and infect cells structural proteins. The packaging 
plasmids include a GAG, POL, and REV. The GAG, a polyprotein that codes the core structural 
proteins; the POL, a reverse transcriptase that generates the cDNa from RNA; and the REV is 
regulator of expression of virion proteins needed to produce viral like particles. Finally, the transfer 
plasmid which is a plasmid that transfer the desired gene. Calcium phosphate transfection 
protocol is one of the methods that is used to create lentiviral particles (Figure 1) [32]. 
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Figure 1: Schematic of calcium phosphate transfection. 
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For transfection, we used human embryonic kidney 293 (H293) cells because they are popular 
for producing recombinant proteins [33]. The transfection efficiency is about 70% (Figure 2). 
 
Figure 2: GFP expression of transfection efficiency. 
Lentiviruses are used because their abilities to integrate in to the cells’ genome of both dividing 
and non-dividing cells. The problem with lentiviruses is their lack of specificity, which can result in 
indiscriminate transduction [34]. The non-specific delivery of therapeutic genes may lead to 
undesirable side effects such as toxicity [35, 36], insertional mutagenesis [35, 36], and 
immunogenicity [35, 36]. The lentiviral vectors have been used successfully to engineer CART19 
cells for patients with advanced leukemia [37]. However, this study is ongoing because the first 
part of it has shown a serious toxic effect in which patients develop cytokine-release syndrome 
[37]. Targeted gene therapy is imperative because it may lower the probability of these 
undesirable side effects and increase the probability of delivering the gene of interest to the 
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desired site. Developing an efficient and safe gene delivery vector has continually been a major 
obstacle to gene delivery [38]. 
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CHAPTER 2: OVERVIEW OF ELASTIN LIKE POLYPEPTIDES 
 
Elastin like polypeptides (ELPs) which are temperature protein-based polymers have been 
used as novel drug carriers [38-40]. ELPs hold beneficial characteristics which are: biocompatible, 
biodegradable, non-immunogenic, and thermo-responsive. They are composed of repeating 
sequences of pentapeptides, (Val-Pro-Gly-X-Gly)n where X can be any amino acids except for 
Proline [41] because it destroys the inverse phase transition [42]. This sequence of pentapeptides 
are derived from the hydrophobic chain of tropoelastin, a soluble form of elastin [43]. Also, ELPs 
are genetically encodable biopolymers that can be fused with any peptides or proteins. ELPs have 
an interesting physical property where they undergo an entropically driven phase transition where 
they are soluble below transition temperature and insoluble above transition temperature [43]. 
This property enables ELPs expressed in bacteria host (such as Escherichia coli) to be purified 
rapidly using inverse temperature cycling (ITC) [44]. ELPs chimeric fusion sequence self-
assembled above transition temperature into nanostructures such as nanoparticles [43, 45] or 
into cross-linked materials [46]. These physical properties of ELPs have been fully elucidated by 
several researchers [47-51]. The benefits of the characteristics of ELPs have led their use for 
medical applications [52] such as scaffolds for tissue engineering [53] and drug delivery [54]. 
2.1 Recombinant ELP Protein Purification 
Inverse temperature cycling (ITC) is used to purify recombinant proteins by a series of cold 
and hot temperatures where the ELPs are soluble below transition temperature (usually in the 
cold spin) and insoluble above transition temperature (usually in the hot spin) (Figure 3). Before 
starting ITC, proteins were constructed. Then for protein production, the gene encoding the 
protein was expressed in the BLRD competent cells which were grown overnight in an agar plate. 
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Figure 3: Transition phase of ELPs above and below transition temperatures. Below 
transition temperature (T < Tt), ELPs are soluble and above transition temperature (T > Tt), 
ELPs are insoluble forming aggregates. 
 
A single colony was selected from the streaked agar plate containing carbenicillin (75uL of 1 
mg/mL stock) for starting a culture of 75 mL of terrific broth media (1 L solution: deionized (DI) 
water, 12 g of tryptone, 24 g of yeast extract, 2.31 g of potassium phosphate monobasic, 12.54 g 
of potassium phosphate dibasic, and 4 mL of 100% Glycerol). This culture was inoculated 
overnight and transferred to a one liter culture the next day (1mL of 1 mg/mL stock of carbenicillin 
was added). This one liter culture was grown overnight and the pelleted bacteria was collected 
by centrifuging the liter culture at 4°C at 3,000 G for 20 minutes. Once the pelleted bacteria is 
collected, bacteria was re-suspended in 160 mL 4°C phosphate buffered saline (PBS) and were 
lysed using a sonicator. The settings were for a total of 12 minutes three cycles with 59 seconds 
pulse on and 59 seconds pulse off, and a 50% amplitude. After each sonicating cycle the bacteria 
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solution was put on ice in a 4°C fridge for 30 minutes. Once the sonication process was 
completed, cellular debris were removed by a centrifugal process of 20,000 G at 4°C for 20 
minutes. Since ELPs are soluble at 4°C, the supernatant was collected and the pellet was 
discarded. ITC process (Figure 4) was proceeded once the supernatant containing the ELPs was 
collected. 
 
Figure 4: Schematic of ELP protein purification using Inverse Temperature Cycling (ITC). 
 
Since salt is a supplement that enhanced the aggregation of ELPs, 2 M of sodium chloride 
(NaCl) was added to the supernatant. The supernatant salt solution was vortexed and incubated 
in a water bath at 42°C for 45 minutes. Above transition temperature ELPs are insoluble. 
Therefore, in the water bath, the solution becomes cloudy which means that the ELPs are 
insoluble. After the incubation time, the ELPs pellet was collected by centrifuging the hot solution 
at 20,000 G at 40°C for 15 minutes. The supernatant from this hot spin was discarded. The pellet 
was re-suspended in 100 mL 4°C PBS. If the ELPs contain cysteines, to prevent disulfide bonds, 
dithiothreitol (DTT) was added in the re-suspended pellet solution. This solution was cooled for 
one hour to allow ELPs to dissolve because they are soluble at 4°C. Then a cold spin was 
performed by centrifugation at 20,000 G at 4°C for 20 minutes. The supernatant was collected 
11 
 
and the ITC cycle of hot and cold spins was repeated at least two more times. After the last hot 
spin, the pellet containing the ELP was re-suspended in 50 mL 4°C DI water. This solution was 
then dialyzed against DI water for a total 48 hours (after 24 hours the old water was discarded 
and fresh water was added) to remove any remaining DTT or salts present. After dialysis, the 
ELPs were lyophilized for 72 hours. 
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CHAPTER 3: DEVELOPMENT OF HETEROGENEOUS ELPS NANOPARTICLES BASED 
 
DELIVERY SYSTEM FOR TARGETED GENE THERAPY 
 
3.1 Introduction 
Genetic diseases caused by a defective gene, single modification in a gene or mutations affect 
millions of people worldwide. People with genetic diseases such as cystic fibrosis [2], cancer [37], 
and Parkinson’s [5] are getting treatments to improve their quality of life but there are no cures for 
these diseases. Gene therapy that aims to deliver a gene of interest to replace, inactivate or 
correct the defective gene to help the diseased tissue function properly is the most promising 
approach for curing these debilitating genetic diseases. Scientists have used multiple gene 
delivery techniques such as lipid mediated gene delivery [8], cationic polymers [9], electroporation 
[10], microinjection [11], and viruses [55]. Due to their efficient mode of gene delivery, viruses 
such as lentiviruses are popular vectors for gene delivery [24]. Lentiviral vectors are attractive 
because they can infect both dividing and non-dividing cells [25-27], and they integrate into the 
cells’ genome [28]. The problem with viruses is their lack of specificity, which can result in 
indiscriminate transduction [34]. The non-specific delivery of therapeutic genes could lead to 
undesirable side effects such as toxicity [35, 36], insertional mutagenesis [35, 36], and 
immunogenicity [35, 36]. The need for targeted therapy is imperative because it could lower the 
probability of these undesirable side effects and increase the probability of delivering the gene of 
interest to the desired site. 
Most recombinant lentiviral vectors in use for gene therapy are pseudotyped by the Vesicular 
stomatitis virus (VSV) glycoprotein G VSV-G [56]. This is primarily because VSV exhibits a very 
robust and pantropic infectivity and also it has been extensively studied and characterized [57]. 
VSV-G pseudotyped lentiviruses exhibit remarkable stability, high transduction efficiency and the 
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same broad tropism as VSV. Thus, currently they are the gold standard for several gene therapy 
procedures [58]. Recent studies have indicated that VSV-G interacts with the low density 
lipoprotein receptor (LDLR) thereby enabling the entry of the virus into the cells [59]. The 
widespread expression of LDLR accounts for the broad applicability of VSV-G pseudotyped viral 
vectors for gene therapy. 
Elastin like polypeptides (ELPs) are gaining popularity as drug delivery vectors [60, 61] due 
to their ability to be genetically encodable and to undergo phase transition [62]. ELPs are protein-
based polymers that have been used as novel drug carriers [38-40]. They are composed of 
repeating sequence of pentapeptides, (Val-Pro-Gly-X-Gly)n where X can be any amino acids 
except for Proline [41] because it destroys the inverse phase transition property of ELPs [42]. This 
sequence of pentapeptides is derived from the hydrophobic chain of tropoelastin, a soluble form 
of elastin [43]. ELPs have an interesting physical property where they undergo an entropically 
driven phase transition rendering them insoluble above the transition temperature [43]. This 
property enables ELPs to be expressed in a bacterial host (such as Escherichia coli) and to be 
purified rapidly using inverse temperature cycling (ITC) [44]. Moreover, since ELPs are genetically 
encodable, chimeric fusion proteins comprising of biologically active motifs and ELPs can be 
synthesized easily [63, 64]. These fusion proteins retain the biological activity of the fused motif 
as well as the phase transitioning property of ELPs, thereby enabling the self-assembly of 
nanostructures such as nanoparticles above the transition temperature [64]. These characteristics 
of ELPs make them attractive targeted delivery vehicles for viral gene delivery. 
Our lab has previously described a heterogeneous nanoparticle delivery system based on 
ELPs that focuses on selective delivery of peptides through selective enhancement of 
macropinocytosis via growth factors [65]. Here we describe the application of the same delivery 
system for targeted delivery of lentiviral particles to high growth factor receptor expressing cells. 
Specifically, we report the construction of heterogeneous nanoparticles comprising of two 
chimeric ELP fusion proteins, namely the low density lipoprotein receptor repeat 3 (LDLR3)-ELP 
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and keratinocyte growth factor (KGF)-ELP. We report that VSV-G pseudotyped lentiviral particles 
bind to the heterogeneous nanoparticles via LDLR3-ELP thereby preventing viral entry in cells. 
We further show that the heterogeneous nanoparticles containing the bound virus are internalized 
in cells overexpressing the keratinocyte growth factor receptor (KGFR) via KGF-ELP, thereby 
resulting in successful targeted transduction. We believe that this approach of selective 
transduction will lead to successful gene therapy treatment with minimum side effects. Moreover, 
the modular nature of the chimeric ELP fusion protein system ensures that this approach can 
easily be used to target any growth factor receptor thereby broadening the applicability of this 
strategy to multiple cell types. 
3.2 Materials and Methods 
3.2.1 Materials 
Dulbecco modified eagle medium (DMEM) and fetal bovine serum (FBS) were purchased 
from Life Technologies. A549, H1650, H23, and H292 cells were kindly donated by Dr. Hara from 
Moffit Cancer Center. Peptide genes and growth factors were purchased from GenScript 
(Piscataway, NJ). H293 cells were purchased from ATCC (Manassas, VA).  
The gel extraction, miniprep, and midiprep kits were purchased from QIAGEN (Valencia, CA). 
RT-PCR reagents were purchased from Bio-Rad (Hercules, CA). The restriction enzymes and 
other enzymes used for cloning were purchases from New England Biolabs (Ipswich, MA). The 
lentiviral plasmids psPAX2 and pMD2.G were a gift from Didier Trono (Addgene plasmid #12259 
and #12260, respectively). The lentiviral gene plasmid, pLVTHM-syndecan-1 shRNA GFP, was 
kindly donated by Dr. Ralph Sanderson from the University of Alabama. 
3.2.2 Cell Culture 
Human lung carcinoma cells, A549 and H292, and human lung adenocarcinoma cells, H23 
and H1650, and human embryonic kidney cells, H293, were cultured in DMEM supplemented 
with 10% FBS and 1% antibiotic antimycotic (AA) in a humidified incubator at 37°C and 5% CO2. 
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3.2.3 Synthesis of LDLR3-ELP and KGF-ELP 
The PUC57 plasmids containing the genes (VPGVG)2VPGCG(VPGVG)2, LDLR3, and KGF 
were purchased from GenScript (Piscataway, NJ). Recursive direction ligation method was used 
to create V40C2 encoding gene as previously described [66]. PflMI and Bgll enzymes were used 
to cut the LDLR3 and KGF genes. A 1.0% agarose gel was used to run these genes. The genes 
were then extracted using QIAquick gel extraction kit. The PflMI was used to linearize the pUC19 
vector containing the ELP sequence and the removed LDLR3 or KGF genes were cloned in with 
the ELP gene.  
The pUC19 vector containing LDLR3-ELP or the KGF-ELP fusion protein gene situated by 
PflMI and Bgll sites. PflMI and Bgll enzymes were used to remove the sequence encoding fusion 
proteins from the pUC19 vector. As mentioned above, a gel extraction was performed to recover 
the sequence encoding fusion proteins. The pET25b+ expression vector was modified to 
incorporate a SfiI cloning site for the LDLR3-ELP or the KGF-ELP fusion protein gene to be 
cloned. Through heat shock at 42°C, the pET25b+ expression vector containing the LDLR3-ELP 
or the KGF-ELP fusion protein gene was transformed into BLRD competent cells. 
3.2.4 Purification of LDLR3-ELP 
For protein production, the BLRD competent cells were grown overnight in an agar plate. A 
single colony was selected from the streaked agar plate containing carbenicillin for starting a 
culture of 75 mL. This culture was inoculated overnight and transferred to a one liter culture the 
next day. This one liter culture was grown overnight and inverse temperature cycling was used to 
purify LDLR3-ELP or the KGF-ELP fusion as previously described [41]. Since LDLR3-ELP have 
six cysteine residues, double amount of the reducing agent dithiothreitol (DTT) was added to the 
cold centrifugation to reduce the formation of disulfide bonds. After the ITC process, the ELP 
fusion proteins solution were dialyzed for 48 hours. They were then lyophilized for 72 hours to be 
stored at room temperature. 
 
16 
 
3.2.5 LDLR3-ELP Total Protein Assay 
The fusion protein LDLR3-ELP purity was conducted using total protein stain assay with 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The lyophilized LDLR3-
ELP was dissolved in 4°C PBS to a final concentration of 2 µM and 10 µM. Both the bacterial 
lysates and the dissolved lyophilized LDLR3-ELP were analyzed by SDS-PAGE (12% acrylamide 
gels). 
3.2.6 Characterization of LDLR3-ELP 
The Dynamic light scattering (DLS) instrument (Zetasizer Nano S, Malver, UK) was used to 
analyze the transition temperature from 4°C to 40°C at a step of 2°C and size of the LDLR3-ELP 
at the body’s physiological temperature, 37°C. Three readings were performed in each 
temperature point with an equilibrium time of 10 minutes. For both transition temperature and 
size, 2 uM of LDLR3-ELP was prepared in 1X phosphate buffered saline (PBS) and 1 mL of the 
solution was inserted into a cuvette for readings. For the transition temperature, readings were 
based on scattered light intensity versus temperature. For the size, readings were based on mean 
intensity versus diameter size at 37°C. 
3.2.7 Labeling of the Fusion Proteins 
For the particle internalization experiments, maleimide chemistry was used to label the 
cysteines that are present in the fusion proteins. Fluorescein-5-maleimide (AnaSpec Inc cat # 
81405) was added to the fusion proteins. The mixture was incubated at room temperature for one 
hour on an orbital shaker. Then it was incubated at 4°C overnight. A series of hot and cold cycles 
were then performed to remove unconjugated fluorescein on a centrifuge at 20,000 G for 10 
minutes each time. In the hot spin, the pellet is collected because above transition temperature 
the protein aggregates. In the cold spin, the supernatant is collected because below transition 
temperature the protein is soluble. Overall, after the hot spin, the supernatant was discarded and 
equal amount of volume of cold sterile PBS was added. Once the pellet is dissolved, the 
17 
 
supernatant was collected at 4°C. The hot and cold cycles were repeated at least two times to 
remove all of the unconjugated fluorescein. 
3.2.8 Internalization Assay for Fusion Proteins 
Cells (20,000/well) were seeded in a 48-wells plate and cultured in DMEM supplemented with 
10% FBS and 1% AA. They were grown until 30% confluency was reached and were starved for 
24 hours then were treated in serum free media with the indicated treatments (labeled 2 µM 
LDLR3-ELP and combination of labeled 2 µM LDLR3-ELP and ELP and KGF-ELP, and LDLR3-
ELP, respectively) for 48 hours. Flow cytometry was used to quantify the data. Before analysis, 
trypan blue was used in each sample suspension to capture only the internalized labeled fusion 
proteins and not the ones that are bound to the periphery of the cells. Flow cytometry was used 
to quantify the data and the normalized fold increase of cell uptake was reported. 
3.2.9 Cytotoxicity Assay 
Cells (20,000/well) were seeded in a 48-wells plate and cultured in DMEM supplemented with 
10% FBS and 1% AA. They were grown until 30% confluency was reached and were starved for 
24 hours then were treated in serum free media with the indicated treatments for 48 hours. After 
their respective treatments, the plate was put on ice for five minutes to dissolve fusion proteins, 
then cells were washed three times with ice-cold sterile PBS. Thiazolyl blue tetrazolium bromide 
(MTT, Acros Organics cat # 298-93-1) was added to each well to a final concentration of 1.2 mM. 
Cells were then incubated for three hours at 37°C. After the incubation time, cells were washed 
once with room temperature sterile PBS to remove the excess MTT medium. Dimethyl sulfoxide 
(DMSO, Fisher Bioreagents cat # BP231-1) was added to solubilize the formazan crystals. For 
data analysis, the EON microplate spectrophotometer (BioTek, Winooski, VT) was used to read 
the absorbance at 570 nm. 
3.2.10 Creation of Lentiviral Particles 
Lentiviral particles were created using calcium phosphate transfection protocol. Transfection 
is the process of creating the lentiviral particles. 
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3.2.10.1 Heat Inactive Media 
FBS was thawed at 37°C. Once thawed, it was incubated in a water bath at 55°C for 30 
minutes. Then filtered with 0.22 µm. Aliquots of 10 mL were made and stored at -20°C. 
3.2.10.2 Viral Plasmid Isolation 
The psPAX2, pMD2.G (Vesicular Stomatitis Virus Glycoprotein-G (VSVG)) and pLVTHM-
syndecan-1 shRNA GFP, were inoculated and grown overnight. The plasmid DNAs were isolated 
as described by QIAGEN midiprep kit.  
3.2.10.3 Calcium Phosphate DNA Co-Precipitation 
The generation of virus from a transient transfection using calcium phosphate precipitation 
protocol as previously described [67] was optimized to create lentivirus particles pseudo typed 
with the VSV-G envelope. Briefly, the day prior transfection, early passage of H293 cells (1 x 
106/well) were seeded in a 6-well plate and cultured in DMEM supplemented with 10% FBS and 
1% AA. They were grown until 70% to 80% confluency is reached. 
Calcium phosphate precipitates were prepared in a 15mL conical tube in master mixes 
sufficient for transfect a 10 mm cell culture dish. Each dish received a solution containing 6 ug of 
DNA (2.90 ug of psPAX2; 0.10 ug of pMD2.G; and 3.0 ug of pLVTHM-syndecan-1 shRNA GFP), 
124 µL of 2 M calcium chloride, 1 mL of 2X HEPES-buffered saline solution (2X HBS), and 858.9 
uL of nuclease free water in a total volume of 2000 µL. DNA was added to nuclease free water in 
the order of psPAX2, pMD2.G, and pLVTHM-syndecan-1 shRNA GFP, then calcium chloride was 
added dropwise to that solution and was left to react for 5 minutes at room temperature. 2X HBS 
was then added at the bottom of the test tube then a 1mL pipette was used to blow bubbles for 
15 seconds. This overall solution was left in room temperature for 30 minutes for precipitates to 
form. 
Prior to adding the calcium phosphate precipitates to the wells, to enhance transfection, 5 µL 
of 50 mM of chloroquine was added to the dish and incubated at 37°C for five minutes. The 
calcium phosphate precipitates (2 mL/dish) were then added to the dish dropwise. After 8 hours, 
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the media was extracted and 10 mL of fresh 37°C DMEM supplemented with 10% FBS and 1% 
AA was added to each well. 
Once 100% confluency is reached between 24 and 48 hours, 10 mL of heat inactive DMEM 
media was added to the dish. The supernatant containing the lentiviral particles was collected 
after 24 hours and filtered with a sterile 0.45 µm filter. Lentiviral particles can be immediately used 
for various assays or stored at -80°C. Transfection efficiency was about 70%. 
3.2.11 Inhibition Assay 
Cells (10,000/well) were seeded in a 24-wells plate and cultured in DMEM supplemented with 
10% FBS and 1% AA. They were grown until 30% confluency was reached. Prior to treatment, 8 
µg of 10 mg/mL of polybrene (Santa Cruz Biotechnology cat# sc-134220) was added to the 
supernatant containing the viral particles to neutralize the virus to allow the cells to uptake them. 
The viral particles were incubated with the NPs prior to cell treatment. Then cells were incubated 
for 24 hours with the virus containing NPs. After 24 hours, the treatment was removed and fresh 
media, DMEM supplemented with 10% FBS and 1% A, was added to each well. Then, 72 hours 
later, the transduction efficiency was quantified using flow cytometry and the normalized fold 
increase GFP-expressing cells was reported. 
3.2.12 Transduction Assay 
Cells (20,000/well) were seeded in a 48-wells plate and cultured in DMEM supplemented with 
10% FBS and 1% AA. They were grown until 30% confluency was reached and were starved for 
24 hours. Prior to treatment, 8 µg of 10 mg/mL of polybrene (Santa Cruz Biotechnology cat# sc-
134220) was added to the supernatant containing the viral particles to neutralize the virus to allow 
the cells to uptake them. The viral particles were incubated with the NPs prior to cell treatment. 
Then the cells were incubated for 24 hours with the virus containing NPs. After 24 hours, the old 
media was discarded and fresh 37°C media containing DMEM supplemented with 10% FBS and 
1% AA was added to each well. Then, 72 hours later after their respective treatments, each plate 
was put on ice for five minutes to dissolve fusion proteins, then cells were washed three times 
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with ice-cold sterile PBS and were trypsinized using 0.25% trypsin (200 uL). The trypsin reaction 
was neutralized by an addition of 200 uL of DMEM supplemented with 10% FBS and 1% AA. 
Solution was then transferred into micro-test tubes and cells were pelleted and re-suspended in 
250 µL of PBS. Then cells were analyzed using flow cytometry and the normalized fold increase 
GFP-expressing cells was reported. 
3.2.13 Binding Assay 
A549 cells (20,000/well) and H293 cells (30,000/well) were seeded in a 48-wells plate and 
cultured in in DMEM supplemented with 10% FBS and 1% AA, respectively. A549 cells were 
grown until 30% confluency was reached and were starved for 24 hours, but not the H293 cells. 
H293 cells were cultured with 10% FBS throughout the experiment since they are sensitive in 
serum free media. Prior to treatment, 8 µg of 10 mg/mL of polybrene was added to virus. The 
virus was incubated at 4°C for 10 minutes. Only LDLR3-ELP was added to the virus and the 
micro-test tubes were incubated at 4°C for 15 minutes. Afterwards, all vials were incubated at 
37°C for 30 minutes. Virus with the treatments were centrifuged at 10,000 G at 37°C for 1 minute. 
A negative control containing the virus was not centrifuged to determine if the centrifuge affected 
the virus throughout the protocol. Supernatant was collected and the pellet was re-suspended in 
an equal amount of 4°C heat inactive media. Both supernatant and re-suspended pellet were 
incubated at 4°C for 15 minutes. Then, ELP, KGF-ELP, and LDLR3-ELP were added respectively.  
All samples, supernatant and re-suspended pellet were then incubated for 30 minutes at 37°C. 
Treatments were added to cells. Then the cells were incubated for 24 hours with the virus 
containing NPs. After 24 hours, the old media was discarded; for the A549 cells fresh 37°C serum 
free media containing DMEM supplemented and 1% AA was added to each well; for the H293 
cells fresh 37°C serum media containing DMEM supplemented with 10% FBS, and 1% AA was 
added to each well. Then, 72 hours later after their respective treatments, the plates were put on 
ice for five minutes to dissolve fusion proteins, cells were then washed with ice-cold sterile PBS. 
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For visualization purposes fluorescent pictures were taken before analysis of flow cytometry. 
Nuclei were counterstained with NucBlue (Life Technologies R37605) and fluorescent pictures 
were taken (20X magnification; bar 200 µm) using EVOS fluorescence microscope (Life 
technologies). Cells were trypsinized using 0.25% trypsin (200 µL). The trypsin reaction was 
neutralized by an addition of 200uL of DMEM supplemented with 10% FBS and 1% AA. Solutions 
were transferred into micro-test tubes and cells were pelleted and re-suspended in 250 µL of PBS. 
Then cells were analyzed using flow cytometry and the normalized fold increase GFP-expressing 
cells and geometric mean of cells were reported. 
3.3 Results 
3.3.1 Fusion Protein Comprising of the Viral Envelope Binding Domain (VBD) and Elastin 
Like Peptide (ELP) was Successfully Expressed and Purified Using Inverse Temperature 
Cycling (ITC) 
Previous studies have shown that the virus pseudotyped with the vesicular stomatitis virus 
glycoprotein-G (VSV-G) envelope enters the cell by binding with the low density lipoprotein (LDL) 
receptor [59]. This binding prevented the virus from infecting the cells. In order to create a fusion 
protein that binds to the virus to prevent the non-selective infection of untargeted cell types, a 
fragment of the LDL receptor gene, LDL receptor repeat 3 (LDLR3), was cloned upstream of the 
elastin like peptide gene (Figure 5). 
Throughout the recursive ligation process, we checked if the LDLR3 gene was successfully 
inserted in the PuC19V40C2 gene after performing a gel electrophoresis; this was done after 
performing the colony polymerase chain (PCR) (Figures 6 and 7). This showed a band at 1000 
base pairs (bp). The self-ligation is below the 1000 bp mark. To make sure that LDLR3-ELP was 
expressed, we cut it with the restriction enzyme PST1 and performed a gel electrophoresis. 
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Figure 5: Schematic of recursive ligation and transformation process of LDLR3-ELP. 
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Figure 6: Schematic of LDLR3-ELP successfully inserted into the ELP gene. 
 
 
Figure 7: LDLR3 was successfully inserted in the Puc19V40C2 plasmid. A gel 
electrophoresis was ran after performing PCR in the cloning competent cells. ELP=V40C2. 
The self-ligation has a band below 1000 bp while LDLR3-V40C2 has a band approximately 
1000pb. 
 
Once the LDLR3-ELP plasmid is cut, a single band at about 4 kb is shown (Figure 8). Finally, 
we showed that LDLR3-ELP was successfully inserted in the expression plasmid PET25b+ after 
performing the colony PCR in the expression competent cells BLRD and running a gel 
electrophoresis (Figure 9). 
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Figure 8: LDLR3-V40C2 was successfully cut by restriction enzyme PST1. An agarose gel 
electrophoresis was ran and a band is shown about 4 kb. 
 
 
Figure 9: LDLR3-V40C2 was successfully inserted in the expression plasmid PET25b+. A 
colony PCR was performed and a gel electrophoresis was ran. The red rectangle shows 
the colony that was pick to express in the expression competent cells BLRD. 
 
We then performed a transformation for the plasmid to be expressed in the expression 
competent cells BLRD. BLRD is the bacterial host (E. Coli) that carries T7 RNA polymerase as a 
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λ lysogen [68]. T7 RNA polymerase allows DNA to be transcribed and is highly specific for T7 
phage promoters. The gene encoding the fusion protein LDLR3-ELP (where ELP is V40C2) was 
then expressed in a bacterial host (E. coli) and purified by inverse temperature cycling (ITC). 
After three ITC cycles, isolated protein was stained with simply safe blue and analyzed for 
purity by SDS-PAGE gel electrophoresis. The single black band with a molecular weight of 50 
kDA shown in figure 10 (with description of each lane in table 3) confirms purity of the LDLR3-
ELP fusion protein. Different concentrations were used to clearly show the black band, a darker 
band at 10 µM and a faded band at 2 µM. 
 
Figure 10: LDLR3-ELP fusion protein was successfully purified using ITC in the 12% SDS-
PAGE gel. 
 
Table 3 Lane descriptions for Figure 10 
Lane Description 
1 Ladder 
2 10uM LDLR3-ELP 
3 2uM LDLR3-ELP 
4 Bacterial Lysate 
5 Bacterial Lysate 
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3.3.2 LDLR3-ELP Maintains the Phase Transition Property and Self-Assembles Into 
Nanoparticles 
Since we were successfully able to purify LDL3-ELP using ITC, it suggests that LDLR3-ELP 
fusion protein retained the physical phase transition property characteristic of ELPs (Figure 11). 
 
Figure 11: LDLR3-ELP design. The top figure represents the sequence of LDLR3-ELP gene 
inserted into the expression vector. The bottom figure represents the LDLR3-ELP fusion 
protein holds the characteristics of ELPs where below transition temperature it is soluble 
and above transition temperature it is insoluble. 
 
To further characterize the phase transitioning property of LDLR3-ELP, dynamic light 
scattering (DLS) was used to analyze the transition temperature of LDLR3-ELP at a concentration 
of 2 µM.  The results show that LDLR3-ELP transitions near 30°C (Figure 12). Previous studies 
described for other ELP based fusion proteins [41] state that at the transition temperature the 
fusion protein form fairly monodispersed aggregates with radii in the nanometer range. To 
ascertain whether this is the case with LDLR3-ELP, we measured the particle size and dispersity 
with DLS at a concentration of 2 µM, at homeostatic physiological temperature 37°C.  The 
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dispersity of proteins was tightly distributed around a mean size of 150 nm with respective 
minimum and maximum sizes of 12 nm and 615 nm with 96.4% of peak 1 area intensity is 204 
nm and 3.6% of peak 2 area intensity is 3.6 nm (Figure 13). A concentration of 2 µM of LDLR3-
ELP was characterized because that is the total concentration used for the experiments 
mentioned in this paper. 
 
Figure 12: LDLR3-ELP transitions near 30°C. Dynamic light scattering (DLS) was used to 
analyze the transition temperature of LDLR3-ELP at a concentration of 2 µM (in PBS) from 
5°C to 40°C. 
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Figure 13: LDLR3-ELP size distribution at the body’s physiological temperature 37°C. DLS 
was used to analyze the size distribution of LDLR3-ELP at a concentration of 2 µM (in PBS) 
at 37°C. The size distribution is presented as mean intensity (%). 
 
3.3.3 LDLR3-ELP Inhibits Virus Infectivity and Does Not Induce Cell Death 
Previous studies have shown that recombinant soluble LDLR (sLDLR) inhibited transduction 
by a lentivirus pseudotyped with the VSV-G envelope [59]. To test if LDLR3-ELP fusion protein 
maintained the activity of the fused LDLR-3 domain (Figure 14), a transduction assay using 
lentiviral particles pseudotyped with the VSV-G envelope and containing the green fluorescent 
protein (GFP) gene was performed. The virus and LDLR3-ELP fusion protein were incubated 
together and then introduced to cells. Indeed, 20 µM of LDLR3-ELP inhibited the viral transduction 
efficiency of more than 99% (Figures 15 and 16). 
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Figure 14: Schematic of LDLR3-ELP binding to the virus in the presence of calcium. 
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Figure 15: Green Fluorescent Protein (GFP) expression in A549 cells of LDLR3-ELP 
inhibiting virus infectivity. A549 cells (20,000/well) were seeded in a 48-wells plate and 
cultured in DMEM supplemented with 10% FBS and 1% AA. They were grown until 30% 
confluency was reached and were starved for 24 hours. Prior to treatment, 8µg of 10mg/mL 
of polybrene was added to the supernatant containing the viral particles to neutralize the 
virus to allow the cells to uptake them. The viral particles were incubated with the NPs 
prior to cell treatment. Then the cells were incubated for 24 hours with the virus containing 
NPs. After 24 hours, the old media was discarded and fresh serum free 37°C media 
containing DMEM supplemented and 1% AA was added to each well. 72 hours later, Nuclei 
were counterstained with NucBlue and fluorescent pictures were taken (20X magnification; 
white bar is 200 µm) using EVOS fluorescence microscope. 
 
Previous studies have reported that sLDLR inhibits virus infectivity by binding to the VSV-G 
envelope of the lentivirus. sLDLR binds to the virus in the presence of calcium. Though our body 
contains calcium, the binding affinity of calcium and LDLR3-ELP was not addressed, we showed 
that the LDLR3-ELP binds with the lentivirus pseudotyped with VSV-G envelope. Then, we 
incubated the virus with different concentrations of LDLR3-ELP fusion protein. The transitioned 
LDLR-3-ELP along with any bound virus was then pelletized by centrifugation and the supernatant 
was collected (Figure 17). The collected supernatant was then put atop of the cells and the 
remaining virus in the supernatant was quantified by measuring the transduction efficiency. 
Indeed, we observed a decrease in transduction efficiency of more than 90% suggesting that the 
most of the virus was bound to the LDLR-3-ELP (Figures 18 and 19). We further performed an 
MTT assay to make sure that LDLR3-ELP was not toxic to cells. Our results indicate that LDLR3-
ELP with a concentration as high as 20 µM is not toxic to cells (Figure 20). 
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Figure 16: Quantification of the GFP expression in A549 cells of LDLR3-ELP inhibiting 
virus infectivity. Average ± SD of the normalized GFP Expression. A549 cells (20,000/well) 
were seeded in a 48-wells plate and cultured in DMEM supplemented with 10% FBS and 
1% AA. They were grown until 30% confluency was reached and were starved for 24 hours. 
Prior to treatment, 8µg of 10mg/mL of polybrene was added to the supernatant containing 
the viral particles to neutralize the virus to allow the cells to uptake them. The viral particles 
were incubated with the NPs prior to cell treatment. Then the cells were incubated for 24 
hours with the virus containing NPs. After 24 hours, the old media was discarded and fresh 
serum free 37°C media containing DMEM supplemented and 1% AA was added to each 
well. 72 hours later, the transduction efficiency was quantified using flow cytometry. 
Treatments were normalized to control (virus). These experiments were repeated two more 
times with triplicates. ***indicates P<0.001 when compared to control (virus). Error bars 
represent ± SD. 
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Figure 17: Schematic of the transitioned LDLR-3-ELP along with any bound virus. 
 
 
Figure 18: GFP expression in A549 cells of LDLR3-ELP inhibiting virus infectivity at 
different concentrations. A549 cells were starved for 24 hours and a binding assay was 
performed. Cells were treated for 24 hours with the virus containing NPs. After 24 hours, 
the old media was discarded, and fresh 37°C serum free media was added to each well. 
Then, 72 hours later Nuclei were counterstained with NucBlue and fluorescent pictures 
were taken (20X magnification; white bar is 200µm) using EVOS fluorescence microscope. 
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Figure 19: Quantification of the GFP expression in A549 cells of LDLR3-ELP inhibiting 
virus infectivity. Average ± SD of the normalized GFP Expression. A549 cells (20,000/well) 
were seeded in a 48-wells plate and cultured in in DMEM supplemented with 10% FBS and 
1% AA. They were grown until 30% confluency was reached and were starved for 24 hours. 
Prior to treatment, 8µg of 10mg/mL of polybrene was added to virus. The virus was 
incubated at 4°C for 10 minutes. Only LDLR3-ELP was added to the virus and the micro-
test tubes were incubated at 4°C for 15 minutes. Afterwards, all vials were incubated at 
37°C for 30 minutes. Virus with the treatments were centrifuged at 10,000g at 37°C for 1 
minute. A negative control containing the virus was not centrifuged to determine if the 
centrifuge affects the virus throughout the protocol. Supernatant was collected and cells 
were treated with the supernatant. Then the cells were incubated for 24 hours with 
treatment in the supernatant. After 24 hours, the old media was discarded, and fresh 37°C 
serum free media containing DMEM supplemented and 1% AA was added to each well. 72 
hours later, the transduction efficiency was quantified using flow cytometry. Treatments 
were normalized to control (virus). These experiments were repeated two more times with 
triplicates. ***indicates P<0.001 when compared to control (virus). Error bars represent ± 
SD. 
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Figure 20: LDLR3-ELP does not induce cell death. A549, H1650, H292, and H23 cells 
(20,000/well) were seeded in a 48-wells plate and cultured in DMEM supplemented with 10% 
FBS and 1% AA. They were grown until 30% confluency is reached and were starved for 
24 hours then were treated in serum free media with the indicated treatments (0.2 µM, 2 
µM, 10 µM and 20 µM LDLR3-ELP) for 48 hours. After 48 hours, a MTT assay was performed 
and a spectrophotometer was used to read the absorbance at 570nm. Treatments were 
normalized to control (no treatment). These experiments were repeated two more times 
with triplicates. ***indicates P<0.001, **indicates P<0.05, and *indicates P<0.1when 
compared to control (no treatment). Error bars represent ± SD. 
 
3.3.4 Targeted Internalization of LDLR3-ELP Using Growth Factors in High Growth Factor 
Receptor Expressing Cells 
Our results clearly indicate that LDLR3-ELP binds to the virus and thus prevents the virus 
from entering and infecting the cells. We reasoned that the virus can selectively be delivered to 
the cells by targeted delivery of LDLR3-ELP to the cells. We have previously described a 
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heterogeneous ELP based nanoparticle delivery platform containing growth factors that 
selectively delivers payload in high growth factor receptor expressing cells. We reasoned that 
targeted gene therapy can be achieved using this platform. To test this hypothesis we created 
heterogeneous nanoparticles (NPs) comprising of keratinocyte growth factor-ELP (KGF-ELP 
which has been previously created in our lab Figure 21) and LDLR3-ELP (Figure 22). Only 2 µM 
of LDLR3-ELP were labeled with maleimide chemistry. Indeed, these heterogeneous NPs were 
selectively able to deliver LDLR-3-ELP in the high KGFR expressing A549 cells (Figure 23). 
 
Figure 21: KGF-ELP design. KGF-ELP fusion protein holds the characteristics of ELPs 
where below transition temperature it is soluble and above transition temperature it is 
insoluble. 
 
 
Figure 22: Schematic of heterogeneous nanoparticle comprising of keratinocyte growth 
factor-ELP (KGF-ELP) and LDLR3-ELP. 
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Figure 23: Targeted internalization of LDLR3-ELP using growth factors in high growth 
factor receptor expressing cells. Average ± SD of the normalized fold increase of cell 
uptake. A549 cells were starved for 24 hours then were treated in serum free media with 
the indicated treatments labeled 2 µM LDLR3-ELP and a combination of labeled 2 µM 
LDLR3-ELP and ELP and KGF-ELP, and LDLR3-ELP respectively, for 48 hours. After 48 
hours, flow cytometry was used to quantify the data. Before analysis of using the flow 
cytometry, trypan blue was used in each sample suspension to capture only the 
internalized labeled fusion proteins and not the ones that are bound to the periphery of the 
cells. These experiments were repeated two more times with triplicates. ***indicates 
P<0.001when compared to control (2 µM LDLR3-ELP). Error bars represent ± SD. 
 
3.3.5 Heterogeneous Nanoparticles Comprising of LDLR3-ELP and KGF-ELP Result in 
Targeted Delivery of the Gene in High Growth Factor Receptor Expressing Cells 
Next, we tested whether the heterogeneous NPs comprised of LDLR-3 ELP and KGF-ELP 
can selectively deliver the VSV-G pseudotyped virus to high growth factor receptor expressing 
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A549 cells thereby resulting in selective transduction. We first performed a transduction assay, 
where we added the virus, LDLR3-ELP, and KGF-ELP together. Figure 24 shows that LDLR3-
ELP blocks the virus infectivity, however, in the presence of KGF-ELP, the transduction efficiency 
increased. Since we did not want free floating virus, we performed a binding assay to test if the 
LDLR3-ELP binds to the virus. Also, we performed a transduction efficiency assay to test different 
concentrations of LDLR3-ELP in the presence of the virus. 
 
Figure 24: KGF-ELP enhanced the transduction efficiency blocked by LDLR3-ELP. A549 
Cells (10,000/well) were seeded in a 24-wells plate and cultured in DMEM supplemented 
with 10% FBS and 1% AA. They were grown until 30% confluency was reached. Prior to 
treatment, 8µg of 10mg/mL of polybrene (Santa Cruz Biotechnology cat# sc-134220) was 
added to the supernatant containing the viral particles to neutralize the virus to allow the 
cells to uptake them. The viral particles were incubated with the NPs prior to cell treatment. 
Then cells were incubated for 24 hours with the virus containing NPs. After 24 hours, the 
treatment was removed and fresh media, DMEM supplemented with 10% FBS and 1% A, 
was added to each well. 72 hours later, the transduction efficiency was quantified using 
flow cytometry and the normalized fold increase GFP-expressing cells were reported. 
These experiments were repeated one more time with duplicates. **indicates P<0.05 when 
compared to control (virus). Error bars represent ± SD. 
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To this end, the virus was incubated with 1 μM LDLR3-ELP and the LDLR3-ELP bound with 
the virus was collected by centrifugation. The pellet containing the LDLR-3-ELP bound with the 
virus was re-suspended in cold media and was then mixed with 1 μM KGF-ELP, resulting in the 
formation of heterogeneous NPs containing the virus and KGF-ELP (Figure 25). 
 
 
Figure 25: Schematic of heterogeneous NPs containing the virus and KGF-ELP. 
39 
 
These heterogeneous nanoparticles have a higher probability of being internalized by high 
growth factor receptor expressing cells (A549 cells) than low growth factor receptor expressing 
cells (H293 cells) (Figures 26 and 27).  
 
Figure 26: Schematic of heterogeneous nanoparticles with virus that have a higher 
probability of being internalized by high growth factor receptor expressing cells (A549 
cells) than low growth factor receptor expressing cells (H293 cells). 
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Figure 27: GFP expression of heterogeneous nanoparticles that have a higher probability 
of being internalized by high growth factor receptor expressing cells (A549 cells) than low 
growth factor receptor expressing cells (H293 cells). A549 cells (20,000/well) and H293 
cells (30,000/well) were seeded in a 48-wells plate and cultured in in DMEM supplemented 
with 10% FBS and 1% AA, respectively. A549 were grown until 30% confluency was 
reached and were starved for 24 hours, but not the H293 cells. H293 cells were cultured 
with 10% FBS throughout the experiment since they are sensitive in serum free media. 
Prior to treatment, 8µg of 10mg/mL of polybrene was added to virus. The virus was 
incubated at 4°C for 10 minutes. Only LDLR3-ELP was added to the virus and the micro-
test tubes were incubated at 4°C for 15 minutes. Afterwards, all vials were incubated at 
37°C for 30 minutes. Virus with the treatments were centrifuged at 10,000g at 37°C for 1 
minute. The pellet was re-suspended in an equal amount of 4°C heat inactive media. The 
re-suspended pellet was incubated at 4°C for 15 minutes. Then, ELP, KGF-ELP, and LDLR3-
ELP were added respectively. Then, all samples of the re-suspended pellet were then 
incubated for 20 minutes at 37°C. Pelleted treatments were added to cells. Then the cells 
were incubated for 24 hours with the virus containing NPs. After 24 hours, the old media 
was discarded, and for A549 cells fresh 37°C serum free media containing DMEM 
supplemented and 1% AA was added to each well, but for the H293 cells fresh 37°C serum 
media containing DMEM supplemented with 10%FBS, and 1%AA was added to each well. 
72 hours later, Nuclei were counterstained with NucBlue and fluorescent pictures were 
taken (20X magnification; white bar is 200 µm) using EVOS fluorescence microscope. 
 
These nanoparticles resulted in a 5.5 fold increase of transduction efficiency in high KGFR 
expressing A549 cells. (Figure 28). On the other hand there was a modest increase of about 1.5 
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fold in H293 cells which have low levels of the KGFR (Figure 28). To determine the number of 
gene copies introduced per cell we quantified the geometric mean of the fluorescence intensity 
and found that there was a 30 % increase in the intensity in A549 cells compared to H293 cells 
(Figure 29), suggesting that multiple viral particles were introduced in the high KGFR expressing 
A549 cells line. 
 
Figure 28: Quantification of GFP expression of heterogeneous nanoparticles that have a 
higher probability of being internalized by high growth factor receptor expressing cells 
(A549 cells) than low growth factor receptor expressing cells (H293 cells). Average ± SD of 
the normalized GFP Expression in A549 cells and H293 cells. A549 cells were starved for 
24 hours and H293 cells treatment started when their confluency reached 30%. A binding 
assay was performed. The pellet was re-suspended in an equal amount of 4°C heat inactive 
media. Then, 1 µM of ELP, KGF-ELP, and LDLR3-ELP were added respectively. Re-
suspended pelleted treatments were added to cells. Then the cells were incubated for 24 
hours with the virus containing NPs. After 24 hours, the old media was discarded, and for 
A549 cells fresh 37°C serum free media was added to each well, but for the H293 cells fresh 
37°C serum media was added to each well. 72 hours later, the transduction efficiency was 
quantified using flow cytometry. Treatments were normalized to control (1µM LDLR3-ELP 
+ 1µM LDLR3-ELP +Virus). These experiments were repeated two more times with 
triplicates. ***indicates P<0.001 and **indicates P<0.05 when compared to control (1 µM 
LDLR3-ELP + 1 µM LDLR3-ELP + Virus). Error bars represent ± SD. 
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Figure 29: Heterogeneous nanoparticles resulted in higher geometric mean in high growth 
factors expressing cells. Average normalized geometric mean of A549 and H293 cells. 
A549 cells (20,000/well) and H293 cells (30,000/well) were seeded in a 48-wells plate and 
cultured in in DMEM supplemented with 10% FBS and 1% AA, respectively. A549 were 
grown until 30% confluency was reached and were starved for 24 hours, but not the H293 
cells. H293 cells were cultured with 10% FBS throughout the experiment since they are 
sensitive in serum free media. Prior to treatment, 8µg of 10mg/mL of polybrene was added 
to virus. The virus was incubated at 4°C for 10 minutes. Only LDLR3-ELP was added to the 
virus and the micro-test tubes were incubated at 4°C for 15 minutes. Afterwards, all vials 
were incubated at 37°C for 30 minutes. Virus with the treatments were centrifuged at 
10,000g at 37°C for 1 minute. The pellet was re-suspended in an equal amount of 4°C heat 
inactive media. The re-suspended pellet was incubated at 4°C for 15 minutes. Then, ELP, 
KGF-ELP, and LDLR3-ELP were added respectively. Then all samples of the re-suspended 
pellet were incubated for 20 minutes at 37°C. Pelleted treatments were added to cells. Then 
the cells were incubated for 24 hours with the virus containing NPs. After 24 hours, the old 
media was discarded, and for A549 cells fresh 37°C serum free media containing DMEM 
supplemented and 1% AA was added to each well, but for the H293 cells fresh 37°C serum 
media containing DMEM supplemented with 10%FBS, and 1%AA was added to each well. 
72 hours later, the transduction efficiency was quantified using flow cytometry. Treatments 
were normalized to control (1µM LDLR3-ELP + 1µM LDLR3-ELP + Virus). These 
experiments were repeated two more times with triplicates. ***indicates P<0.001 and 
**indicates P<0.05 when compared to control (1µM LDLR3-ELP + 1µM LDLR3-ELP + Virus). 
Error bars represent ± SD. 
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3.3.6 ELP and KGF-ELP Do Not Bind to the virus 
To confirm that the increase in transduction efficiency demonstrated by the heterogeneous 
NPs is not because of KGF binding with the viral particles, we tested whether KGF-ELP or ELP 
binds to the virus (Figures 30 and 31). To this end, the virus and either 12 μM ELP or KGF-ELP 
were incubated together and centrifuged. Cells were then treated with the supernatant and the 
transduction efficiency was assessed. Indeed, neither the ELP nor the KGF-ELP treatment of the 
virus resulted in a decrease in transduction efficiency of the viral supernatant (Figures 32 and 33) 
thus suggesting that neither of them bound to the virus. 
 
Figure 30: Schematic of ELP not binding to the virus. 
 
 
Figure 31: Schematic of KGF-ELP not binding to the virus. 
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Figure 32: GFP expression of ELP and KGF-ELP that do not bind to the virus. A549 cells 
(20,000/well) were seeded in a 48-wells plate and cultured in in DMEM supplemented with 
10% FBS and 1% AA. They were grown until 30% confluency was reached and were starved 
for 24 hours. Prior to treatment, 8µg of 10mg/mL of polybrene was added to virus. The virus 
was incubated at 4°C for 10 minutes. Treatments, 12 µM ELP, 12 µM KGF-ELP, and 2 µM 
LDLR3-ELP were added respectively to the virus and the micro-test tubes were incubated 
at 4°C for 15 minutes. Afterwards, all vials were incubated at 37°C for 30 minutes. Virus 
with the treatments were centrifuged at 10,000 G at 37°C for 1 minute. A negative control 
containing the virus was not centrifuged to determine if the centrifuge affected the virus 
throughout the protocol. Supernatant was collected and the pellet was re-suspended in an 
equal amount of 4°C heat inactive media. Both supernatant and the re-suspended pellet 
were incubated at 4°C for 15 minutes. Then all samples, supernatant and the re-suspended 
pellet were incubated for 30 minutes at 37°C. Treatments were added to cells. Then the 
cells were incubated for 24 hours with the virus containing NPs. After 24 hours, the old 
media was discarded, and fresh 37°C serum free media containing DMEM supplemented 
and 1% AA was added to each well. 72 hours later, Nuclei were counterstained with 
NucBlue and fluorescent pictures were taken (20X magnification; white bar is 200 µm) 
using EVOS fluorescence microscope. 
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Figure 33: Quantification of GFP expression of ELP and KGF-ELP that do not bind to the 
virus. Average ± SD of the normalized GFP expression of supernatant. A549 cells 
(20,000/well) were seeded in a 48-wells plate and cultured in in DMEM supplemented with 
10% FBS and 1% AA. They were grown until 30% confluency was reached and were starved 
for 24 hours. Prior to treatment, 8µg of 10mg/mL of polybrene was added to virus. The virus 
was incubated at 4°C for 10 minutes. Treatments, 12µM ELP, 12µM KGF-ELP, and 2µM 
LDLR3-ELP were added respectively to the virus and the micro-test tubes were incubated 
at 4°C for 15 minutes. Afterwards, all vials were incubated at 37°C for 30 minutes. Virus 
with the treatments were centrifuged at 10,000g at 37°C for 1 minute. A negative control 
containing the virus was not centrifuged to determine if the centrifuge affected the virus 
throughout the protocol. Supernatant was collected and the pellet was re-suspended in an 
equal amount of 4°C heat inactive media. Both supernatant and the re-suspended pellet 
were incubated at 4°C for 15 minutes. Then all samples, supernatant and re-suspended 
pellet were incubated for 30 minutes at 37°C. Treatments were added to cells. Then the 
cells were incubated for 24 hours with the virus containing NPs. After 24 hours, the old 
media was discarded, and fresh 37°C serum free media containing DMEM supplemented 
and 1% AA was added to each well. Then, 72 hours later, the transduction efficiency was 
quantified using flow cytometry. Treatments were normalized to control (virus). These 
experiments were repeated two more times with triplicates. ***indicates P<0.001 when 
compared to control (virus). Error bars represent ± SD. 
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3.3.7 Statistical Analysis 
For statistical significance, the p value was calculated for the indicated groups using ANOVA 
single factor.  For the significance of the p values are: ***indicates P<0.001, **indicates P<0.05, 
and *indicates P<0.1. The reported errors indicated the ± SD. 
3.4 Conclusion 
Targeted gene therapy is essential to lower the probability of side effects such as 
immunogenicity, toxicity, and insertional mutagenesis. Our work demonstrates an approach of 
using macropinocytosis pathway for selective uptake of the heterogeneous nanoparticles (NPs) 
with targeting cells that overexpress growth factor receptors. Specifically, the heterogeneous NPs 
consist of the low density lipoprotein receptor 3 (LDLR3)-ELP and the keratinocyte growth factor 
(KGF)-ELP. LDLR3-ELP is used because it was found that LDLR3, a section of the cell-surface 
glycoprotein LDLR, binds with VSV-G envelope in the presence of calcium [59]. The LDLR3 
binding affinity to the VSV-G envelope allows LDLR3 to inhibit VSV infectivity [59]. Therefore, to 
prevent the virus from infecting undesired cells, we used the fusion protein LDLR3-ELP as our 
viral envelope binding domain. KGF-ELP is used as a targeted protein. 
Our work demonstrates that the fusion protein LDLR3-ELP binds to the virus, lentiviral 
particles pseudo typed with the VSV-G envelope containing the green fluorescent protein (GFP) 
gene, and does not induce cell death while the ELP and KGF does not bind to the virus. To add 
selectivity, we used the targeting protein, KGF-ELP. The presence of KGF-ELP allows cells to 
uptake LDLR3-ELP. Though the mechanism of the internalization of LDLR3-ELP in the presence 
of KGF-ELP was not addressed, it is possible that macropinocytosis may take part of the 
internalization due to the presence of the growth factor [65]. In the presence of the virus, our data 
shows that the heterogeneous NPs have a higher probability of getting internalized by cells that 
overexpress the KGF receptors compared to cells that have low KGFR expression. 
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CHAPTER 4: DISCUSSION 
 
 Gene therapy is a promising technique for the treatment of many debilitating genetic diseases, 
such as cystic fibrosis and cancer. Targeted gene therapy is essential because it may lower the 
probability of side effects including toxicity [35, 36], insertional mutagenesis [35, 36], and 
immunogenicity [35, 36]. Viruses, such as lentiviruses, are attractive options for gene therapy 
because they can integrate into the cells’ genome [28] and infect both dividing and non-dividing 
cells [25-27]. Here, we described a novel approach that results in the selective internalization of 
the virus in cells that overexpress keratinocyte growth factor receptors, thereby delivering the 
gene to the targeted cells. Specifically, we created heterogeneous nanoparticles comprising of 
two chimeric fusion proteins namely low density lipoprotein receptor 3 (LDLR3)-ELP and 
keratinocyte growth factor (KGF)-ELP. We show that the heterogeneous nanoparticles deliver the 
virus selectively to high KGF receptor expressing cells resulting in selective delivery of the gene 
encoding green fluorescent protein to those cells. 
 Our experiments indicate that LDLR3-ELP inhibited transduction by a lentivirus pseudotyped 
with the vesicular stomatitis virus glycoprotein G (VSV-G) envelope. We further demonstrated 
that this inhibition was mediated by the binding of the LDLR3-ELP to the virus. This inhibition is 
similar to previous studies that have shown that recombinant soluble LDLR (sLDLR) inhibited 
transduction by a lentivirus pseudotyped with the VSV-G envelope [59]. This study further 
demonstrated that the inhibition was mediated by the binding of the sLDLR to the VSV-G 
envelope, thereby preventing the virus from binding to the LDL receptor on the target cells and 
denying its entry. We believe that LDLR3-ELP blocks viral transduction in a similar fashion. The 
binding of the LDLR3-ELP to the virus also indicates that the binding ability of LDLR3 remained 
unaffected because of the fusion. This observation is similar to previous studies by several others 
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and us for chimeric ELP fusion proteins where the biological activity of the functional domain 
remains unaffected by the ELP fusion [43, 63, 64]. Moreover, the inhibitory activity of LDLR3-ELP 
without KGF-ELP demonstrates that it can be a potential application as an agent in antiviral 
therapy. 
 Viruses can infect multiple cells causing undesired side effects. Thus, to minimize side effects, 
it is essential to selectively deliver the virus only to the target cells. We further show that 
heterogeneous nanoparticles comprising of LDLR3-ELP and KGF-ELP can induce selective 
transduction of VSV-G pseudotyped virus in high KGFR expressing cells. Though the experiments 
described here do not address the mechanism of the selective transduction, it is possible that the 
KGF-ELP in the heterogeneous nanoparticle enhances the internalization of the virus bound to 
the LDLR3-ELP via macropinocytosis; this has been shown previously for other heterogeneous 
ELP based nanoparticle systems in our lab [65]. While several nanoparticulate systems have 
been developed for the targeted delivery of plasmids [69] or SiRNA [70], very few studies focus 
on the selective delivery of viruses for targeted gene therapy. For example, the use of magnetic 
nanoparticles loaded with adenoviral vectors for gene delivery to stented arteries has been 
described [71]. It is to be noted that a magnetic field was used to achieve site specific delivery in 
that approach. A similar approach involving magnetic nanoparticles and lentivirus has been 
described for the transduction of endothelial cells [72] and the delivery of oncolytic adenovirus 
[73]. Nonetheless, the targeted approach described in this work is different than these strategies 
as it focuses on the ligand receptor interactions as opposed to providing a magnetic field for site 
specific delivery. Moreover, applying site directed magnetic field in various parts of the body could 
be challenging as opposed to simply targeting the receptors for gene delivery. 
 Interestingly, we observed a 5.5 fold increase of the GFP gene expression in high KGFR 
expressing cells when treated by the virus in the presence of heterogeneous nanoparticles. We 
believe that this can further be improved upon by creating a single homogeneous nanoparticle 
comprising of KGF-ELP-LDLR3 fusion protein. This will prevent the formation of nanoparticles 
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that solely contain either LDLR3-ELP or KGF-ELP; both of which are a possibility in the case of 
heterogeneous nanoparticles. These studies are currently underway in our lab to further increase 
the selective transduction efficiency. 
 Important characteristics of ELP include: they can undergo self-assembly at a transition 
temperature; they are genetically encodable; they are immunogenic; and they are biocompatible. 
We demonstrated that the fusion protein, LDLR3-ELP, maintained the phase transition property 
and self-assembled into nanoparticles above transition temperature. These fusion proteins 
retained the biological activity and phase transitioning properties of ELPs, as shown in previous 
studies [43, 63, 64]. This allowed recombinant expression and simple purification of the fusion 
proteins by a series of hot and cold spins. Self-assembly is important because this quality allows 
for the creation of chimeric nanoparticles comprising of different chimeric fusion proteins such as 
KGF-ELP and LDLR3-ELP, as described here. Additionally, synthetic genes encoding any ELP 
fusion proteins can easily be synthesized using standard molecular biology approaches. Thus, 
this approach can easily be broadened to include other growth factors to target other cells 
expressing different growth factor receptors such as epidermal growth factor receptor (EGFR) or 
nerve growth factor receptor (NGFR).  
 In summary, we have developed a novel nanoparticle based delivery system for targeted 
delivery of the virus to cells. Delivering the virus to the target cells selectively has been a major 
challenge. We demonstrated that the chimeric ELP fusion protein heterogeneous NPs consisting 
of LDLR3-ELP as a viral binding domain and KGF-ELP as a targeting protein, can overcome this 
challenge. This novel design may help target specific cells and can be used as an application for 
treatment of genetic diseases while limiting side effects of non-targeted gene delivery. 
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CHAPTER 5: FUTURE DIRECTIONS 
 
5.1 Creating a Fusion Protein Consisting of LDLR3 Fused With KGF-ELP 
To improve the fold increase, we would like to eliminate the possibilities of having empty 
particles (Figure 34). We have a 5.5 fold increase in cells that have high expression of KGF 
receptor and we can always improve this fold by creating a peptide consisting of LDLR3 fused 
with KGF-ELP. 
 
 
 
Figure 34: Schematic of undesired nanoparticles combinations. 
 
We would like to create the desired combinations of having KGF-ELP and LDLR3-ELP (Figure 
35). This should prevent the formation of empty nanoparticles; solely LDLR3-ELP without the 
51 
 
KGF-ELP, or solely KGF-ELP without the LDLR3-ELP. Future studies are to focus on creating a 
single peptide KGF-ELP-LDR3. This consists of both LDLR3 and KGF-ELP where the LDLR3 
acts as the viral binding domain and the KGF acts as the targeting protein. To do this we will 
perform a recursive ligation transformation process (Figures 36 and 37). Once the peptide is 
transformed into the BLRD cells, we can purify it using inverse temperature cycling (ITC) and test 
for its purification. 
 
 
Figure 35: Schematic of desired nanoparticles combinations. 
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Figure 36: Schematic of recursive ligation and transformation process of KGF-ELP-LDLR3. 
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Figure 37: KGF-ELP-LDLR3 design.  The top figure represents the sequence of KGF-ELP-
LDLR3 gene inserted into the expression vector. The bottom figure represents KGF-ELP-
LDLR3 fusion protein holding the characteristics of ELPs where below transition 
temperature it is soluble and above transition temperature it is insoluble. 
 
Once we obtain the desired protein, LDLR3-KGF-ELP, we will first incubate it with the virus at 
4°C so that the virus can bind to the LDLR3 then we will incubate the solution at 37°C (Figure 38). 
 
Figure 38: Schematic of desired nanoparticle, KGF-ELP-LDLR3, at 4°C and 37°C. 
 
If we incubated the virus and the protein together at 37°C instead of 4°C, there could be a 
possibility that the nanostructures without the virus could be formed (Figure 39). 
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Figure 39: Possible combinations of nanoparticles, KGF-ELP-LDLR3 formation at 37°C in 
the presence of virus. 
 
We believe that this particle can enhance the fold increase of selectively targeted high growth 
factor receptors cells (eg. KGFR) (Figure 40). 
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Figure 40: Schematic of heterogeneous nanoparticles of KGF-ELP-LDR3 with the virus that 
have a higher probability of being internalized by high growth factor receptor expressing 
cells (A549 cells) than low growth factor receptor expressing cells (H293 cells). 
 
We would also like to create the homogeneous peptide KGF-ELP-LDLR3 so that another 
peptide that can only fused to ELP can be inserted. To do this we will perform a recursive ligation 
transformation process (Figure 41). Once the peptide (Figure 42) is transformed into the BLRD 
cells, we can purify it using inverse temperature cycling (ITC) and test for its purification. 
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Figure 41: Schematic of recursive ligation and transformation process of KGF-ELP-LDLR3. 
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Figure 42: LDLR3-KGF-ELP design.  The top figure represent the sequence of LDLR3-KGF-
ELP gene inserted into the expression vector. The bottom figure represents the LDLR3-
KGF-ELP fusion protein holding the characteristics of ELPs where below transition 
temperature it is soluble and above transition temperature it is insoluble. 
 
Once we obtain the desired protein, LDLR3-KGF-ELP, we will first incubate it with the virus at 
4°C so that the virus can bind to the LDLR3 then we will incubate the solution at 37°C (Figure 43). 
 
Figure 43: Schematic of desired nanoparticle, LDLR3-KGF-ELP, at 4°C and 37°C. 
 
If we incubated the virus and the protein together at 37°C instead of 4°C, there could be a 
possibility that the nanostructures without the virus could be formed (Figure 44). 
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Figure 44: Possible combinations of nanoparticles, LDLR3-KGF-ELP at 37°C in the 
presence of virus. 
 
We do not want empty particles. Once the protein is incubated at 4°C then we will incubate 
that solution at 37° so the heterogeneous nanoparticles with the virus can be formed. The final 
product we would like is either KGF-ELP-LDLR3 or LDLR3-KGF-ELP to improve the fold increase. 
5.2 Testing Longevity of Transduction Efficiency 
We would like to test the longevity of the transduction efficiency by checking when the cell 
divides if the new daughter cell obtains the desired gene that was delivered to the parent cell. We 
would study the geometric mean and the transduction efficiency. Geometric mean (GM) tells you 
the intensity of the cells. This means that if there are multiple viral particles that one cell 
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expresses, it will fluoresce a brighter green than a cell that has fewer viral particles. There can be 
multiple possibilities that can happen, where all the viral particles can be expressed in one cell or 
can be distributed among other cells. This distribution allows for a higher transduction efficiency 
(expression of green fluorescent protein (GFP) gene) (Figure 45). 
 
Figure 45: Comparison of high geometric mean and high expression GFP. 
 
5.3 Testing the Internalization Pathway of LDLR3-ELP in the Presence of KGF-ELP 
Since we do not want toxicity, immunogenicity, or insertional mutagenesis to occur we added 
a targeted protein to add selectivity. The targeting protein that we used is KGF-ELP. The presence 
of KGF-ELP allows cells to uptake LDLR3-ELP. Though the mechanism of the internalization of 
LDLR3-ELP in the presence of KGF-ELP was not addressed, it is possible that macropinocytosis 
may take part of the internalization due to the presence of the growth factor [65]. Macropinocytosis 
has been well studied by others and they have shown that growth factors can enhance it [65]. 
Cells can uptake particles through different pathways such as receptor-mediated endocytosis and 
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macropinocytosis [74-76]. The macropinocytosis pathway is beneficial in comparison to the 
receptor-mediated endocytosis. In the macropinocytosis pathway, large vacuoles called 
macropinosomes, greater than1 µm, allow uptake of large particles [77-79]. However, the 
receptor-mediated endocytosis allows uptake of particles that are less than 200 nm [78-80]. 
Since macropinosomes are naturally leaky, the particles internalized by cells in the 
macropinocytosis pathway escape the lysosomal degradation [76], but in receptor-mediated 
endocytosis particles are trapped in the endosomes followed by enzymatic degradation in 
lysosomes [76]. Finally, during a macropinocytosis pathway multiple nanoparticles can be 
internalized by cells due to the cell surface ruffling induced upon stimulation by the growth factor 
[76, 79] while in receptor-mediated endocytosis cells can uptake one particle at a time [76]. We 
would like to perform an experiment to test the pathway of LDLR3-ELP in the presence of KGF-
ELP and to confirm if it gets internalized via macropinocytosis. 
5.4 Using Different Growth Factor Receptors 
There are multiple routes to deliver drugs to the body. The routes of administration include: 
oral, parenteral, inhalation, intrathecal, rectal, and topical. Based on the type of cell that needs to 
be targeted, the type of administration varies. There are multiple types of growth factors receptors; 
epidermal growth factor receptors, fibroblast growth factor receptors, platelet-derived growth 
factor receptors, nerve growth factor receptors, insulin growth factor receptors, and neurotrophic 
growth factor receptors. A way that we can deliver the heterogeneous nanoparticles is based on 
the cells that high expression of the growth factor (Figure 46). This will help to selectively target 
cells in the gene therapy field. 
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Figure 46: Schematic of selectivity of nanoparticles to high expression growth factor cells. 
 
Our work demonstrates an approach of for selective uptake of the heterogeneous 
nanoparticles (NPs) with targeting cells that overexpress growth factor receptors. Specifically, the 
heterogeneous NPs consist of the low density lipoprotein receptor 3 (LDLR3)-ELP and the 
keratinocyte growth factor (KGF)-ELP. The chimeric ELP fusion protein system ensures that it is 
easily fused to any growth factor receptor to broaden the application for selective uptake of the 
heterogeneous nanoparticles (NPs) to multiple cell types, depending on growth factor expression.  
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This approach allows for delivery of the heterogeneous NPs in different parts of the body based 
on the overexpression of growth factor in the targeted cells. Growth factors such as epidermal 
growth factor (EGF) and nerve growth factor (NGF) can be fused to ELP (Figures 47 and 48). 
 
Figure 47: EGF-ELP design. The top figure represents the sequence of EGF-ELP gene 
inserted into the expression vector. The bottom figure represents the EGF-ELP fusion 
protein holding the characteristics of ELPs where below transition temperature it is soluble 
and above transition temperature it is insoluble. 
 
Overexpression of the EGF receptor gene leads to rapid growth of cancer cells [81]. Studies 
have shown potential therapies for glioblastoma, a tumor developed in the brain due to the 
amplification and mutation of the EGFR gene, are limited by acquired drug resistance [81]. We 
can use our approach of including LDLR3 and EGF-ELP in the heterogeneous NPs to deliver a 
gene that can deactivate the mutated EGFR gene in order to stop the cells from growing rapidly. 
Studies have shown that NGFR is produced abnormally in high amounts of cancer cells, leading 
to inactivation of the tumor suppressor, p53, causing the cancer cells to grow rapidly [82]. We can 
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use our approach of including LDLR3 and NGF-ELP to deliver a gene that can activate the tumor 
suppressor, p53, so that it can activate NGFR transcription to suppress tumor growth. 
 
Figure 48: NGF-ELP design. The top figure represents the sequence of NGF-ELP gene 
inserted into the expression vector. The bottom figure represents the LDLR3-ELP fusion 
protein holding the characteristics of ELPs where below transition temperature it is soluble 
and above transition temperature it is insoluble. 
 
Currently, scientists are using the overexpression of EGFR in glioblastoma multiforme (GBM) 
tumor cells to deliver the therapeutic gene (cetuximab), an anti-EGFR antibody, directly to the 
central nervous system using an adeno-associated virus serotype rh.10 gene transfer vector 
(AAVrh.10CetMab Vector) to reduce GBM tumor growth [83]. Though this study showed reduction 
in tumor growth, however, it did not eliminate these cells. That could lead to the possibility that 
the tumor cells will grow again; therefore a higher dosage maybe needed to reduce the GBM 
tumor growth. We could create nanoparticles consisting of EGF-ELP-LDLR3 (Figure 49). 
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Figure 49: EGF-ELP-LDLR3 design. The top figure represents the sequence of EGF-ELP-
LDLR3 gene inserted into the expression vector. The bottom figure represents the EGF-
ELP-LDLR3 fusion protein holding the characteristics of ELPs where below transition 
temperature it is soluble and above transition temperature it is insoluble. 
 
To do this we will perform a recursive ligation transformation process (Figure 50). Once the 
peptide is transformed into the BLRD cells, we can purify it using inverse temperature cycling 
(ITC) and test for its purification. Also we would like to add a peptide that can kill the cancer cells. 
Therefore we would have heterogeneous nanoparticles consisting of EGF-ELP-LDLR3 and P-
ELP (Figures 51 and 52). Then we will perform a recursive ligation transformation process of P-
ELP (Figure 53) and purify it using ITC. 
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Figure 50: Schematic of recursive ligation and transformation process of EGF-ELP-LDLR3. 
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Figure 51: P-ELP design. The top figure represents the sequence of P-ELP gene inserted 
into the expression vector. The bottom figure represents the P-ELP fusion protein holding 
the characteristics of ELPs where below transition temperature it is soluble and above 
transition temperature it is insoluble. P is the peptide that is toxic to cancer cells. 
 
 
Figure 52: Schematic of heterogeneous nanoparticle comprising of EGF-ELP-LDLR3 and 
P-ELP. P is the peptide that is toxic to cancer cells. 
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Figure 53: Schematic of recursive ligation and transformation process of P-ELP. P is the 
peptide that is toxic to cancer cells. 
 
Due to the benefits of the chimeric ELP fusion protein system of fusing to any growth factor 
receptors or peptides, our approach can have the LDLR3-ELP binding to the virus which 
preventing the virus from infecting cells; have EGFR as a targeting protein; have a knock out gene 
that can prevent the glioblastoma cells from proliferating and also; have another peptide that can 
kill cancer cells fused with the ELP. We can try to create the peptide LDLR3-EGF-ELP-P (Figure 
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54) or EGF-LDLR3-ELP-P (Figure 55). We can do this by recursive ligation and transformation 
process (Figure 56) and purify it using ITC. 
 
Figure 54: LDLR3-EGF-ELP-P design. The top figure represents the sequence of LDLR3-
EGF-ELP-P design gene inserted into the expression vector. The bottom figure represents 
the LDLR3-EGF-ELP-P design fusion protein holding the characteristics of ELPs where 
below transition temperature it is soluble and above transition temperature it is insoluble. 
 
 
Figure 55: EGF-LDLR3-ELP-P design. The top figure represents the sequence of EGF-
LDLR3-ELP-P design gene inserted into the expression vector. The bottom figure 
represents the EGF-LDLR3-ELP-P design fusion protein holding the characteristics of 
ELPs where below transition temperature it is soluble and above transition temperature it 
is insoluble. 
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Figure 56: Schematic of recursive ligation and transformation process of LDLR3-EGF-ELP-
P. P represents the peptide that is toxic to cancer cells. 
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For selectivity, when using the EGF-ELP-LDLR3, the nanoparticle will most likely get 
internalized by cells with high EGFR than cells with low EGFR (Figure 57). 
 
Figure 57: Schematic of heterogeneous nanoparticles of EGF-ELP-LDR3 with virus that 
have a higher probability of being internalized by high growth factor receptor expressing 
cells preventing cells from proliferating. 
 
If the nanoparticle is solely EGF-ELP-LDLR3 and P-ELP we can test the ratio of EGF-ELP-
LDLR3 to P-ELP to assess the concentration of each particle and also perform a proliferation 
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assay and a cytotoxicity assay. We believe the addition of the P-ELP with EGF-ELP-LDLR3 
means that the cancer cells will not proliferate and they will die (Figure 58). 
 
Figure 58: Schematic of heterogeneous nanoparticles of EGF-ELP-LDR3-P with virus that 
have a higher probability of being internalized by high growth factor receptor expressing 
cells preventing cells from proliferating. 
 
5.5 Using the Heterogeneous Nanoparticles for Lung Injuries 
A lung injury can be caused by inhalation of foreign particles such as those from cigarette 
smoke, dysfunctional autoimmune system, and many more. If the foreign particles are not 
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removed by the mechanism of the mucociliary clearance, they can be engulfed by the 
macrophages [84]. However, viruses can surpass the lung defense and prolong in the 
macrophages. When foreign particulates surpass the lung defense and stay in the lung, this 
causes the body to send signals such as chemoattractants through the process called chemotaxis 
[85]. This results in an increase in pro-inflammatory cytokines, chemokines and effector cells such 
as macrophages and neutrophils, leading to an increase in inflammation [86, 87]. Figure 59 below 
summarizes one way that elastin degradation occurs from the formation of lung injury. 
 
Figure 59: Schematic of lung injury to elastin degradation. 
In lung injuries, cytokines, chemokines, and effector cells are overexpressed. Normally alveoli 
type two cells (AECII) differentiate to alveoli type I cells (AECI) since the AECI cannot proliferate 
and they die during an injury [88]. Since the rate of elastase activity is higher than the rate of 
AECII differentiation, the amount of AECII in the body starts decreasing resulting in elastin 
degradation leading to emphysema [89]. Mediators that cause elastin degradation are targeted to 
decrease the elastin degradation.  
The imbalance of oxidant and antioxidant occurs because of high concentrations of oxidants 
and free radicals that are coming in the body; the oxidants that are produced and released in the 
body; and the inactivation of the antiproteases. This imbalance leads to oxidative stress creating 
an antiprotease/protease imbalance, inflammation, and cell apoptosis resulting in the inactivation 
of antiproteases, and degradation of alveoli elasticity by the increased amount of the elastase 
activity [90, 91]. While the activity of elastase increases, the amount of inflammation also 
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increases, and the occurrence of apoptosis also increases leading to an imbalance of protease 
and antiprotease. 
Creating gene delivery vectors has been challenging because these vectors have to be able 
to surpass the body’s natural immune system to reach the targeted site and also incorporate the 
gene that can get activated and stay stable [92]. This paper will focus on two lung injuries, 
emphysema and cystic fibrosis (CF). Emphysema is a type of chronic obstructive pulmonary 
diseases that is characterized by airflow limitation [90, 93] and the degradation in the elasticity of 
the alveoli and increased in collagen [94]. Emphysema can because caused by the cigarette 
smoke damaging alveoli walls or by naturally having alpha-1 antitrypsin (AAT) deficiency. There 
are 3.4 million of adults diagnosed with emphysema in the United States [95]. Currently there is 
no cure for emphysema. 
We propose the development of recombinant elastin like peptides (ELPs) composing of 
LDLR3-ELP and growth factor (GF)-ELP that can be used as a delivery system to incorporate a 
persistent gene. Specifically in this work, we propose the development of nanoparticles that can 
be used as a delivery system that can incorporate the gene SERPINA-1 or pro-inflammatory 
inhibitor to repair the elasticity of the alveoli. We chose the SERPINA-1 gene because it encodes 
the normal form of AAT. Due to the imbalance between the antioxidants and oxidants that can 
cause emphysema from cigarette smoke, delivering a pro-inflammatory inhibitor is essential [91]. 
5.6 Testing for Immunogenicity 
The immune system protects the body from infections and malignancies [96, 97]. When 
delivering viruses to the body, there is a likely chance of immunogenicity to occur. Immunogenicity 
is the process of inducing the immune response to foreign antigens in the body. Immunogenicity 
limits the use of treatment because it can lead to production of antidrug antibodies [98] and result 
in loss of efficacy [99]. Since lentivectors are intrinsically immunogenic [100], we would like to 
perform an immunogenic test. We will evaluate pro-inflammatory signaling pathways and the 
activation of TLR3 and TLR7 as previously described in previous studies [97]. 
74 
 
5.7 Using LDLR3-ELP as an Antiviral Drug for Respiratory Syncytial Virus 
Viruses are small infectious agents that use the cell mechanism and that can infect all life 
forms such as animals and plants. Viruses can infect cells in the blood [101], liver [102], and the 
respiratory system [103]. When viruses infect and reproduce in the host cells they can cause 
diseases such as influenza [104], shingles [105], herpes [106], and human immunodeficiency 
virus/acquired immune deficiency syndrome (HIV/AIDS) [107]. Vaccines have been used to 
reduce the number of viral diseases such as chickenpox (varicella) [108], polio [109], and measles 
[110]. However, there are challenges that are faced to create vaccines or drugs that can prevent 
viral infections for diseases like HIV/AIDS and shingles while being safe and effective for the 
human being. Strategies to prevent and treat viral infections are challenging because viruses 
adapt the cell mechanism, live in the cells, and may lead to morbidity and mortality. While LDLR3-
ELP can be used for targeted gene therapy with the presence of KGF-ELP, it can also be used 
as an antiviral drug. 
One of the virus infection that is being focused is the respiratory syncytial virus (RSV) 
infection. RSV can enter the body through coughs, sneeze, and droplets. It causes moderate-to-
severe acute and lower respiratory infection [111] in children and is estimated that 66,000-
199,000 children younger than 5 years died from RSV-associated acute lower respiratory infection 
in 2005 [112]. This leads to a majority of children’s’ hospitalization for bronchiolitis [113], 
pneumococcal pneumonia and Haemophilus influenza type b [114]. RSV not only affects children, 
but it also affects the elderlies from age 65 and older [115] which can cause them to have 
pneumonia [113], exacerbation of chronic obstructive pulmonary disease (COPD) [113, 116] and 
acute deterioration [113]. RSV, a member of the paramyxovirus family [117], entry requires an 
attachment protein (HN, H, or G) that binds to a cellular receptor and a fusion protein (F) that 
drives membrane merger [118, 119]. Though the mechanism of RSV entry to a cell is not fully 
elucidated, it is thought that when RSV infects by binding the fusion (F) protein to TLR4 receptor. 
Due to this binding, the G protein acts as an antigen signaling immune cells [113, 120]. Therefore, 
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most researchers focus on inhibiting the binding of fusion F to prevent RSV infection. The scientific 
rationale to inhibit RSV infection is to develop drugs that can interfere with virus attachment, 
fusion, or intracellular replication [113]. Some of the drugs that have been used for preventing or 
inhibiting RSV infection are: antibodies [121]; fusion inhibitors [122]; and nucleoside analogs. 
Drugs such as palivizumab, a humanized monocle antibody, is used against RSV F protein by 
preventing the spread of the virus to the lower respiratory tract [113, 123, 124]; ribavirin, a 
nucleoside analog [125], is used to inhibit inosine monophosphate dehydrogenase (IMPDH) 
reducing formation of mRNA and viral polymerase [113, 126]; and BMS-433771, VP-14637, RFI-
641, and JNJ-2408068 are small molecules that inhibits RSV fusion [113, 127, 128]. However, 
these drugs have efficacy and toxicity issues [117]. Recently SAH-RSVF peptides, a stabilized α-
helices of RSV-F, has been developed and has shown to prevent nasopulmonary RSV infection 
[129]. Though this peptide is a combination of peptide stapling and nanoparticles, it still has to 
expand in the clinical route. Currently a nucleoside analog, ALS-008176 has shown to significantly 
reduce RSV viral load and it is ongoing in clinical trials [125]. With the knowledge that is obtained 
from current research to inhibit RSV infection, the combination biomaterials that bind with the F 
fusion protein and deal with cholesterol is essential. 
This study will focus on using LDLR3-ELP with the heptad repeat 1 (HR1) analog (5-Helix) 
fused with ELP, 5-Helix-ELP; this combination inhibits respiratory syncytial virus (RSV) infectivity. 
5-Helix was found to interact with the heptad repeat of the virus and this interaction inhibits RSV 
viral entry. Many therapeutic strategies are being developed to create antiviral drugs that can 
prevent and treat viral infection, especially RSV. This study will focus on the targeted and antiviral 
activities of LDLR3-ELP with the presence of recombinant ELPs. 
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APPENDIX A: AMINO ACID SEQUENCE FOR KGF, LDLR3, 5-HELIX, AND ELP 
 
Table A Sequence and molecular weight information of KGF, LDLR3, 5-HELIX, and ELP 
Protein Sequence 
Molecular 
weight 
ELP 
VPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVP
GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGV
GVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGV
PGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPG
VGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVG
VPGVGVPGVGVPGVGVPGVGVPGVGVPGCGVPGVGVP
GVGVPGVGVPGVGVPGCGVPGVGVPGVG 
20500 Da 
KGF 
MHKWILTWILPTLLYRSCFHIICLVGTISLACNDMTPEQMAT
NVNCSSPERHTRSYDYMEGGDIRVRRLFCRTQWYLRIDK
RGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAM
NKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNG
GEMFVALNQKGIPVRGKKTK KEQKTAHFLPMAIT 
22509 Da 
LDRL3 PPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASC 4355 Da 
5-HELIX 
KVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLHLK
NYIDKQFLGSSGGDEFDASISQVNEKINQSLAFIRKSDELL
HNVNAGKSTINGGSGGKVLHLEGEVNKIKSALLSTNKAVV
SLSNGVSVLTSKVLHLKNYIDKQFLGSSGGSDEFDASISQ
VNEKINQSLAFIRKSDELLHNVNAGKSTINGGSGGKVLHLE
GEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLHLKNYIDKQ
FL 
26162 Da 
 
